ACR Management of Giant Cell Arteritis and Takayasu Arteritis Guideline Summary - Guideline Central

Design and created by Guideline Central in participation with the American College of Rheumatology.

Document Overview

Document Title: Management of Giant Cell Arteritis and Takayasu Arteritis

Authoring Society: American College of Rheumatology

Document Publication Date: Jul 7, 2021

Page Last Reviewed/Updated: May 5, 2026

Document Type: Guideline

Country of Publication: United States

Full Text Freely Available: Yes

Full Text Guideline: onlinelibrary.wiley.com/doi/10.1002/art.41774

Source Citation: Maz M, Chung SA, Abril A, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis & Rheumatology, Vol. 73, No. 8, August 2021, pp 1349–1365. doi 10.1002/art.41774

Document Scope, Criteria, and Use Cases

Document Objectives: To provide evidence-based recommendations and expert guidance for the management of giant cell arteritis (GCA) and Takayasu arteritis (TAK) as exemplars of large vessel vasculitis.

Scope: Assessment and Screening, Diagnosis, Management, Treatment

Diseases/Conditions (MeSH)

D056653 - Rheumatoid Vasculitis

D014657 - Vasculitis

D013700 - Giant Cell Arteritis

D013625 - Takayasu Arteritis

D056653 - Rheumatoid Vasculitis

D014657 - Vasculitis

D013700 - Giant Cell Arteritis

D013625 - Takayasu Arteritis

Keywords: GCA, Takayasu arteritis, giant cell arteritis, vasculitis

Target Patient Population: patients with giant cell arteritis (GCA) and Takayasu arteritis (TAK)

Inclusion Criteria: Male, Female, Adolescent, Adult, Child, Older Adult

Health Care Settings: Ambulatory

Intended Users: Nurse, Nurse Practitioner, Physician, Physician Assistant

Recommendation Development Processes & Methodology

Supplemental Methodology Resources: Data Supplement Data Supplement Data Supplement Data Supplement Data Supplement

Number of Source Documents: 105

Includes peer/external review process?: Yes

Includes public comment process?: No

Methodologist involvement?: Yes

Patient involvement?: Yes

Includes multi-disciplinary group?: Yes

Includes systematic review?: Yes

Grades quality of strength of evidence?: Yes

Grades quality of strength of recommendation?: Yes

Discloses funding source?: Yes

Discloses conflicts of interest?: Yes

Includes benefits/harms analysis with recommendations?: No